FDA Goes After Supplement Manufacturers Making Health Claims

FDA Goes After Supplement Manufacturers Making Health Claims

The FDA appears to be taking a tougher stance on supplement manufacturers that make unsubstantiated claims that their products can treat or cure disease.

The FDA on Monday said it sent 17 warning or advisory letters to companies selling supplements that the firms touted treat Alzheimer’s disease. The agency said that the “products may be ineffective, unsafe and could prevent a person from seeking an appropriate diagnosis and treatment.”

Separately, FDA Commissioner Scott Gottlieb signaled that the agency would be taking steps to protect the public from potentially dangerous supplements, as well as seek to have more regulation over the industry. Unlike drugs, supplements don’t have to go through the same level of scrutiny before they hit the market.

This is thanks to the Dietary Supplement Health and Education Act (DSHEA) of 1994, which puts the onus the FDA to show a supplement is unsafe. And while the law requires that supplement manufacturers notify the FDA they are making a supplement, they don’t have to tell the agency what goes into it.

In a statement, Gottlieb said that the industry has grown exponentially since the DSHEA came out. In 1994, supplements were a $4 billion industry with about 4,000 products. Now, according to Gottlieb, it is worth about $40 billion and has as many as 80,000 products.

“I’m concerned that changes in the supplement market may have outpaced the evolution of our own policies and our capacity to manage emerging risks,” Gottlieb said. “To continue to fulfill our public health obligations we need to modernize and strengthen our overall approach to these products.”

He added he will start a “public dialogue” to see if changes to the DSHEA are necessary.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Diabetes, Fertility Supplements, Nootropics

Diabetes, Fertility Supplements, Nootropics

Supplements are sold without review or approval of the FDA. They are not allowed to make specific health claims, but general ones, such as “improves well-being” and “boosts energy” are legal.  That leaves the door open for unscrupulous, or careless, manufacturers. The FDA also does not regulate the manufacturers recommended…

Vitamin E, the Source of Mystery Vaping Illness

Vitamin E, the Source of Mystery Vaping Illness

A “breakthrough” in the investigation of vaping illness and death, EVALI, has been announced by Federal health officials and the CDC (Centers for Disease Control).

  • Advertisement